A recent report indicated that glycosylation of PD-L1 led to the block of recognition of PD-L1/PD-1 by monoclonal antibodies and a low response rate of anti-PD-L1/PD-1 therapy in breast cancer (11). This evidence concerns the gene PDCD1 and breast carcinoma.